Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals released its first commercial-scale cGMP batch of PH-762 drug substance, cleared via Certificate of Analysis and Certificate of Compliance. The validated material supports supply for a planned Phase 2b clinical study expected to begin in the first quarter of 2027.
Key figures
- Drug Name
- PH-762
- Phase Of Trial
- Phase 2b (planned, initiation Q1 2027)
- Phase1b trial nct
- NCT06014086
- Phase2b initiation
- Q1 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.